Healthy Clinical Trial
— PORPHY-ONEOfficial title:
Evaluation of the Protective Effects of a Novel Dietary Microalgae Supplement (PeLiv) Following Exercise-induced Muscle Damage and Influence on Endurance Capacity After Prolonged Consumption
Verified date | September 2023 |
Source | Microphyt |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this investigation is to examine the effects of consuming a new dietary microalgae based supplement vs. placebo on neuromuscular function, energy utilization, soreness, perceptual wellness, swelling, and markers of muscle damage and inflammation in healthy young men before and after an acute exercise-induced muscle damage protocol (downhill running), and influence on endurance capacity after prolonged consumption.
Status | Completed |
Enrollment | 80 |
Est. completion date | August 18, 2023 |
Est. primary completion date | August 1, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 35 Years |
Eligibility | Inclusion Criteria: - Male participants - Healthy as assessed by Medical and activity history questionnaire (MHQ) - Recreationally active according to American College of Sports Medicine guidelines - Able to provide written and dated informed consent to participate in the study Exclusion Criteria: - Untrained - Any response of "yes" on the PAR-Q+ - Physical limitations preventing running, countermovement jump, and strength (peak isometric torque and peak isokinetic torque) assessments |
Country | Name | City | State |
---|---|---|---|
United States | University of Central Florida | Orlando | Florida |
Lead Sponsor | Collaborator |
---|---|
Microphyt | University of Central Florida |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Neuromuscular function | isokinetic peak torque in Newton per meter (N/m) | From 0 to week 4 | |
Secondary | Energy utilization (Oxygen consumption - VO2) | Running economy during a 5-minute run at 80% of the speed at VO2max with gaz exchange analyzis | From 0 to week 4 | |
Secondary | Energy utilization (Oxygen consumption - VO2) | Running economy during a 5-minute run at 80% of the speed at VO2max with gaz exchange analyzis | From 0 to week 8 | |
Secondary | Isokinetic neuromuscular function | peak torque in Newton per meter (N/m) | From 0 to week 8 | |
Secondary | Isometric neuromuscular function | peak torque in Newton per meter (N/m) | From 0 to week 8 | |
Secondary | Endurance capacity | Maximal oxygen consumption (VO2max) determined during graded exercise test | From 0 to week 4 | |
Secondary | Endurance capacity | Maximal oxygen consumption (VO2max) determined during graded exercise test | From 0 to week 8 | |
Secondary | Soreness and perceptual wellness | Evaluated using using a 100-point numerical pain rating scale anchored with 0= no pain to 100= the most intense pain sensation imaginable after exercise-induced muscle damage protocol | From 0 to week 4 | |
Secondary | Soreness and perceptual wellness | Evaluated using using a 100-point numerical pain rating scale anchored with 0= no pain to 100= the most intense pain sensation imaginable after exercise-induced muscle damage protocol | From 0 to week 8 | |
Secondary | Swelling - Muscle thickness (mm or cm) | Evaluated using musculoskeletal ultrasound | From 0 to week 4 | |
Secondary | Swelling - overall thigh circumference (mm or cm) | Evaluated using musculoskeletal ultrasound | From 0 to week 4 | |
Secondary | Creatine kinase (UI/I) | Blood marker analyzis | After 4 weeks of supplementation | |
Secondary | lactate dehydrogenase (U/L) | Blood marker analyzis | After 4 weeks of supplementation | |
Secondary | Myoglobin (ug/l) | Blood marker analyzis | After 4 weeks of supplementation | |
Secondary | Interleukin-6 (pg/ml) | Blood marker analyzis - inflammation | After 4 weeks of supplementation | |
Secondary | Tumor necrosis factor-a (ug/ml) | Blood marker analyzis - inflammation | After 4 weeks of supplementation | |
Secondary | C-reactive protein (mg/l) | Blood marker analyzis - inflammation | After 4 weeks of supplementation | |
Secondary | Isometric Neuromuscular function | Peak torque in Newton per meter (N/m) | From 0 to week 4 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |